The Latest

  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    10 clinical trials to watch in the second half of 2024

    Study results are expected for two closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs.

  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead’s CMO to depart next year

    Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.

  • J&J HQ
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    In strengthening Spravato sales, a positive sign for psychedelic drugs

    Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Caribou lays off staff; Roche walks away from Relay

    Caribou is slashing its workforce by 12%. Elsewhere, a CDMO is investing in GLP-1 drug demand and Beam’s CFO is returning to J.P. Morgan.

  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Stadtratte via Getty Images
    Image attribution tooltip

    NGM, now private, raises $122M for redrawn research plans

    The Series A round was led by healthcare investor The Column Group, which made the 17-year-old biotechnology company private earlier this year.

  • A person works in Sionna Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Sionna Therapeutics
    Image attribution tooltip

    Sionna revives AbbVie’s cystic fibrosis drugs, eyeing a shot at Vertex

    The startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    The erosion of Humira’s U.S. sales is expected to accelerate, with analysts at Leerink Partners predicting a year-over-year sales decline of 32% when AbbVie reports earnings next week.

    Updated May 13, 2024
  • Red human heart drawing on blue background
    Image attribution tooltip
    Jolygon via Getty Images
    Image attribution tooltip

    Cardurion raises another $260M to fuel heart drug pipeline

    The financing, which ranks as one of the year’s larger private rounds, will help the startup advance a pair of drugs and potentially acquire other medicines. 

  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex sues US over limits on providing fertility services to Casgevy patients

    In the suit, Vertex argues HHS’ stance forces a “Hobson’s choice” on people with sickle cell seeking to undergo the potentially curative treatment.

    Updated July 16, 2024
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    Asceneuron raises another $100M for Alzheimer’s drug development

    The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has intrigued both healthcare investors and pharma venture arms.

  • The Vertex Pharmaceuticals building in daylight on the Boston Seaport.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip
    Gene editing

    Vertex taps Orum to hunt for better ‘preconditioning’ drugs

    The deal gives Vertex rights to use Orum’s ADC-like technology to discover gentler preparatory regimens for patients receiving intensive treatments like Casgevy.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Eli Lilly’s proposed $3.2 billion acquisition of Morphic Holdings extends the industry’s streak of dealmaking involving immune disease drugmakers.

    Updated July 8, 2024
  • Colorful DNA double helix.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Lexeo gene therapy shows signs of heart benefit in small study

    The biotech, which went public late last year, argued the results justify exploring an accelerated approval. But shares fell by double digits amid investor skepticism.

  • Pancreatic cancer cells are stained pink in this micrograph image.
    Image attribution tooltip
    OGphoto via Getty Images
    Image attribution tooltip

    Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data

    Updated results show the biotech's RAS inhibitor shrank pancreatic tumors in 20% to 25% of study participants, but with high rates of side effects like rash and nausea.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Leqembi sales inch higher; Spark’s pivot leads to layoffs

    Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, a well-funded DNA sequencing startup landed one of the year’s larger private funding rounds.  

  • BMS corporate sign
    Image attribution tooltip
    Courtesy of BMS
    Image attribution tooltip

    Bristol Myers’ leukemia blockbuster set to face generic rivals

    Patent litigation has opened the door to generic copies of Bristol Myers’ Sprycel arriving in the U.S. as soon as September.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Twelve biotechs went public between January and June, surpassing 2023's total over the same period but falling short of the pace set in each of the previous five years.

    Updated 16 minutes ago
  • People pass an office building with signage spelling Pfizer in New York City.
    Image attribution tooltip
    George Clerk via Getty Images
    Image attribution tooltip

    Pfizer thinks it found its obesity pill

    Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines. 

  • A person holds an insulin pen
    Image attribution tooltip
    agrobacter via Getty Images
    Image attribution tooltip

    Novo’s once-weekly insulin rejected by FDA

    The FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes treatment in late-stage testing. 

  • Loper decision ending Chevron deference doctrine
    Image attribution tooltip
    Anna Moneymaker / Staff via Getty Images
    Image attribution tooltip
    Deep Dive

    FDA’s lab-developed test rule could be first test of agency’s power post-Chevron

    The Supreme Court’s decision to overturn the Chevron doctrine would make it easier to challenge agency regulations, such as the LDT final rule.

    FDA
  • A person in a blue suit speaks at a lectern.
    Image attribution tooltip
    Jerod Harris via Getty Images
    Image attribution tooltip

    Flagship raises $3.6B for biotech investing

    The latest round of funding comes as the biotech company creator adds executives and prepares to grow more life sciences startups.

  • A photograph of Amylyx Pharmaceuticals cofounders Josh Cohen and Justin Klee.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx, with GLP-1 buy, doubles down on blood sugar drugs

    Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

  • Federal Trade Commission Chair Lina Khan testifies at a committee hearing.
    Image attribution tooltip
    Chip Somodevilla via Getty Images
    Image attribution tooltip

    FTC to sue three largest PBMs over drug price practices: WSJ

    Antitrust regulators are set to file suit against CVS Caremark, Express Scripts and Optum Rx over how they negotiate discounts for drugs, including insulin, per the report.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    As GLP-1 drugs boom, other healthcare companies are cashing in

    With more Americans taking obesity medications, adjacent businesses are offering supportive services to offset side effects, collect data and document new health benefits.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    AbbVie names new R&D head; Arcutis eczema cream approved

    Roopal Thakkar will succeed Tom Hudson as AbbVie’s top scientist. Elsewhere, Skyhawk is advancing its Huntington’s drug and Zevra is preparing for an FDA advisory committee meeting.